Avenue Therapeutics (an associate company of Cipla), a company focused on the development of intravenous (IV) tramadol for the U.S. market, on 11 December 2019 announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
